Vertaling van "therapeutics " (Nederlands → Frans) :

Sandoz – Oriel Therapeutics On June 1, Sandoz completed the acquisition of the privately held US based Oriel Therapeutics Inc., to broaden its portfolio of projects in the field of respiratory drugs for a total purchase consideration of USD 329 million.
Sandoz – Oriel Therapeutics Le 1 er juin, Sandoz a terminé l’acquisition d’Oriel Therapeutics Inc., une entreprise américaine non cotée, afin d’élargir son portefeuille de projets dans le domaine des médicaments respiratoires. Le prix d’achat s’élève à USD 329 millions.

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

Sandoz – Oriel Therapeutics On June 1, Sandoz completed the acquisition of the privately held US based Oriel Therapeutics Inc., to broaden its portfolio of projects in the field of respiratory drugs for a total purchase consideration of USD 332 million.
Sandoz – Oriel Therapeutics Le 1 er juin, Sandoz a terminé l’acquisition d’Oriel Therapeutics Inc., une entreprise américaine non cotée, afin d’élargir son portefeuille de projets dans le domaine des médicaments respiratoires. Le prix d’achat s’élève à USD 332 millions.

Pharmaceuticals – Nektar pulmonary business On October 21, Novartis agreed to acquire Nektar Therapeutics Inc’. s pulmonary business unit for USD 115 million in cash.
Pharmaceuticals – activités de Nektar dans le domaine pulmonaire Le 21 octobre, Novartis a convenu d'acquérir de Nektar Therapeutics Inc. sa branche des médicaments pulmonaires pour un montant d’USD 115 millions en espèces.

Pharmacopoeia Unit II is also charged with the Pharmacopoeia/ Therapeutical Magistral Formularium (TMF - FTM) service and ensures the secretariat of the Belgian Pharmacopoeia commission in collaboration with the European Pharmacopoeia commission.
Pharmacopoeia Unit II is also charged with the Pharmacopoeia/ Therapeutical Magistral Formularium (TMF - FTM) service and ensures the secretariat of the Belgian Pharmacopoeia commission in collaboration with the European Pharmacopoeia commission.

It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.
It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.

the trade in food supplements with therapeutic indications (and in some cases the infringement of intellectual property rights) ●● Racketeering involving narcotics and psychotropic substances in the form of medicines ●● Problems relating to the import, export and
the trade in food supplements with therapeutic indications (and in some cases the infringement of intellectual property rights) ●● Racketeering involving narcotics and psychotropic substances in the form of medicines ●● Problems relating to the import, export and

This accounting policy was applied for the first time in the second quarter of 2010 for the Corthera Inc., and Oriel Therapeutics Inc., acquisitions discussed in note 3 below.
Cette politique comptable a été appliquée pour la première fois au deuxième trimestre 2010 aux acquisitions de Corthera Inc. et d’Oriel Therapeutics Inc., détaillées dans la note 3 ci-après.

All therapeutic franchises delivered strong underlying growth.
Tous les domaines thérapeutiques ont réalisé une excellente croissance sous-jacente.

Pharmaceutical net sales by therapeutic area – Third quarter (unaudited)
Chiffre d’affaires net par domaine thérapeutique – troisième trimestre (non audité)